-
Je něco špatně v tomto záznamu ?
Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse
M. Mlynarcikova, J. Balcarkova, P. Mickova, V. Scudla, T. Pika, J. Bacovsky, J. Minarik, E. Janousova, M. Jarosova,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT14400
MZ0
CEP - Centrální evidence projektů
- MeSH
- chromozomální aberace * MeSH
- cytogenetické vyšetření MeSH
- dospělí MeSH
- geny myc MeSH
- hybridizace in situ fluorescenční MeSH
- imunofenotypizace MeSH
- Kaplanův-Meierův odhad MeSH
- klonální evoluce MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidské chromozomy, pár 8 * MeSH
- mnohočetný myelom diagnóza genetika mortalita terapie MeSH
- nádorové biomarkery MeSH
- progrese nemoci MeSH
- recidiva MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: The genome of multiple myeloma (MM) clonal plasma cells is characterized by genetic changes of prognostic importance. Disease progression is accompanied by a number of secondary chromosomal aberrations including chromosome 8. We focused on the detection of chromosome 8 aberrations in patients with MM who were examined at 2 different phases: diagnosis and progression/relapse. PATIENTS AND METHODS: A total of 62 patients with MM were examined at the time of diagnosis and at relapse/progression. The median age was 64 years (range, 39-78 years); the study included 29 males and 33 females. We analyzed bone marrow samples for detecting aberrations on chromosome 8 by the fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) and fluorescence in situ hybridization methods with specific probes. RESULTS: Chromosome 8 aberrations were detected in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. Only 5 (8%) patients developed additional chromosome 8 changes at progression/relapse. The aberrations were heterogeneous, involving numerical and structural changes of the MYC gene. Aberrations of the short arm of chromosome 8, involving the genes TRAIL-R1/-R2, were less frequent (4 of 62 patients, 6.4%). All aberrations of chromosome 8 were accompanied with additional changes and with an advanced clinical phase of the disease. This finding significantly influenced the overall survival of patients. CONCLUSION: In the current study, chromosome 8 aberrations were highly heterogeneous, were presented at diagnosis in patients with advanced clinical stage, and were associated with worse overall survival. We have not confirmed the increase of frequency aberration of chromosome 8 in disease progression. The findings demonstrate the importance of fluorescence in situ hybridization examination of chromosome 8 in newly diagnosed patients with MM.
Department of Hemato oncology Palacky University Hospital Olomouc Czech Republic
Institute of Biostatistics and Analysis Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024085
- 003
- CZ-PrNML
- 005
- 20191107133112.0
- 007
- ta
- 008
- 170720s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clml.2016.02.038 $2 doi
- 035 __
- $a (PubMed)27052024
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mlynarcikova, Miroslava $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic.
- 245 10
- $a Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse / $c M. Mlynarcikova, J. Balcarkova, P. Mickova, V. Scudla, T. Pika, J. Bacovsky, J. Minarik, E. Janousova, M. Jarosova,
- 520 9_
- $a BACKGROUND: The genome of multiple myeloma (MM) clonal plasma cells is characterized by genetic changes of prognostic importance. Disease progression is accompanied by a number of secondary chromosomal aberrations including chromosome 8. We focused on the detection of chromosome 8 aberrations in patients with MM who were examined at 2 different phases: diagnosis and progression/relapse. PATIENTS AND METHODS: A total of 62 patients with MM were examined at the time of diagnosis and at relapse/progression. The median age was 64 years (range, 39-78 years); the study included 29 males and 33 females. We analyzed bone marrow samples for detecting aberrations on chromosome 8 by the fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) and fluorescence in situ hybridization methods with specific probes. RESULTS: Chromosome 8 aberrations were detected in 24 (38.7%) patients at diagnosis and in 29 (46.8%) patients at progression/relapse. Only 5 (8%) patients developed additional chromosome 8 changes at progression/relapse. The aberrations were heterogeneous, involving numerical and structural changes of the MYC gene. Aberrations of the short arm of chromosome 8, involving the genes TRAIL-R1/-R2, were less frequent (4 of 62 patients, 6.4%). All aberrations of chromosome 8 were accompanied with additional changes and with an advanced clinical phase of the disease. This finding significantly influenced the overall survival of patients. CONCLUSION: In the current study, chromosome 8 aberrations were highly heterogeneous, were presented at diagnosis in patients with advanced clinical stage, and were associated with worse overall survival. We have not confirmed the increase of frequency aberration of chromosome 8 in disease progression. The findings demonstrate the importance of fluorescence in situ hybridization examination of chromosome 8 in newly diagnosed patients with MM.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a nádorové biomarkery $7 D014408
- 650 12
- $a chromozomální aberace $7 D002869
- 650 12
- $a lidské chromozomy, pár 8 $7 D002898
- 650 _2
- $a klonální evoluce $7 D060965
- 650 _2
- $a cytogenetické vyšetření $7 D020732
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a geny myc $7 D016259
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunofenotypizace $7 D016130
- 650 _2
- $a hybridizace in situ fluorescenční $7 D017404
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mnohočetný myelom $x diagnóza $x genetika $x mortalita $x terapie $7 D009101
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a recidiva $7 D012008
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Balcárková, Jana $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. $7 xx0085195
- 700 1_
- $a Mickova, Pavla $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic.
- 700 1_
- $a Ščudla, Vlastimil, $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. $d 1946- $7 jn20000402953
- 700 1_
- $a Pika, Tomáš $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. $7 xx0071238
- 700 1_
- $a Bačovský, Jaroslav $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. $7 xx0053311
- 700 1_
- $a Minařík, Jiří $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. $7 xx0106330
- 700 1_
- $a Koriťáková, Eva, $u Institute of Biostatistics and Analysis, Masaryk University, Brno, Czech Republic. $d 1986- $7 xx0159601
- 700 1_
- $a Jarošová, Marie, $u Department of Hemato-oncology, Palacky University Hospital, Olomouc, Czech Republic. Electronic address: Marie.Jarosova@fnol.cz. $d 1950- $7 xx0053403
- 773 0_
- $w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 16, č. 6 (2016), s. 358-365
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27052024 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20191107133344 $b ABA008
- 999 __
- $a ok $b bmc $g 1239766 $s 984998
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 16 $c 6 $d 358-365 $e 20160227 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
- GRA __
- $a NT14400 $p MZ0
- LZP __
- $a Pubmed-20170720